Skip to main content
Fig. 3 | Cardiovascular Diabetology

Fig. 3

From: Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study

Fig. 3

Kaplan–Meier plots of hospitalization for heart failure in all patients (a), and baseline cardiovascular stratifications with underlying cardiovascular disease (b), and without underlying cardiovascular disease (c). DPP-4i dipeptidyl peptidase-4 inhibitor, hHF hospitalization for heart failure

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840